NASDAQ:ABMD - ABIOMED Stock Price, Price Target & More

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) posted its quarterly earnings results on Thursday, May, 3rd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.16. The medical equipment provider had revenue of $174.44 million for the quarter, compared to the consensus estimate of $164.30 million. ABIOMED had a return on equity of 17.58% and a net margin of 18.89%. The firm's revenue for the quarter was up 39.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.33 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for ABIOMED.

8 Wall Street analysts have issued twelve-month price targets for ABIOMED's stock. Their predictions range from $280.00 to $480.00. On average, they expect ABIOMED's share price to reach $363.1429 in the next twelve months. View Analyst Ratings for ABIOMED.

Some companies that are related to ABIOMED include Stryker (SYK), Becton Dickinson and (BDX), FRESENIUS SE &/S (FSNUY), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE) and Cantel Medical (CMD).

Media stories about ABMD stock have trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ABIOMED earned a media sentiment score of 0.03 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 45.41 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.35%), Baillie Gifford & Co. (4.62%), Palo Alto Investors LP (3.04%), Winslow Capital Management LLC (1.77%), American Century Companies Inc. (1.75%) and Franklin Resources Inc. (1.41%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Millennium Management LLC, American Century Companies Inc., Wells Fargo & Company MN, Sei Investments Co., Scout Investments Inc., Blair William & Co. IL and OppenheimerFunds Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Paul Thomas and William J Bolt. View Insider Buying and Selling for ABIOMED.

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Franklin Resources Inc., BlackRock Inc., JPMorgan Chase & Co., Rockefeller Capital Management L.P., Prudential Financial Inc., Baillie Gifford & Co. and FIL Ltd. View Insider Buying and Selling for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $427.29.

ABIOMED has a market capitalization of $19.01 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]